ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 587

Detection of Structural Lesions on T1 Weighted MRI Versus Radiography of the Sacroiliac Joints in Early Axial Spa: 2-Year Data

Walter P. Maksymowych1, Pascal Claudepierre2, Manouk de Hooge3, Robert G. Lambert4, Robert B.M. Landewé5, Anna Molto6, Désirée van der Heijde3, Jack F Bukowski7, Heather Jones8, Isabelle Logeart9, Lisa Marshall8, Ronald Pedersen10, Annette Szumski11, Bonnie Vlahos12 and Maxime Dougados13, 1Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, 2Universite Paris Est Creteil, Paris, France, 3Leiden University Medical Center, Leiden, Netherlands, 4University of Alberta, Edmonton, AB, Canada, 5Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, 6Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, 7Clinical Affairs, Pfizer, Collegeville, PA, 8Inflammation & Immunology Global Medical Affairs, Pfizer, Collegeville, PA, 9Medical Affairs, Pfizer, France, Paris, France, 10Department of Biostatistics, Pfizer, Collegeville, PA, 11inVentiv Health, Princeton, NJ, 12Clinical Sciences, Pfizer, Collegeville, PA, 13Hopital Cochin, Paris Descartes University, Paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: axial spondyloarthritis and radiography, Lesions, MRI

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: At the SI joint (SIJ) level, several methods exist for evaluating structural damage, e.g., MRI, CT scan, radiographs. In EMBARK (NCT01258738) and DESIR (NCT01648907), MRI and radiographs were available at baseline and Week 104. We evaluated: (1) the association between presence/absence of erosion on MRI and presence/absence of erosion or sacroiliitis on radiographs at the SIJ at baseline and Week 104, and (2) the association between decrease/increase in erosion on MRI and decrease/increase in erosion or sacroiliitis on radiographs at the SIJ between baseline and Week 104.

Methods: Patients in both studies had early axial SpA (axSpA). EMBARK included a 12-week double-blind placebo-controlled period, then open-label etanercept for 92 weeks. DESIR patients had no history of biologic therapy and did not receive biologics for 2 years. MRI and radiographs of the SIJ from DESIR and EMBARK were combined and anonymized; readers were unaware of film chronology and original patient cohort. Three experienced readers evaluated T1 weighted MRI images using the SpondyloArthritis Research Consortium of Canada (SPARCC) SIJ Structural Score (SSS), graded radiographic sacroiliitis using the modified New York grading system, and recorded the presence/absence of individual radiographic lesions (erosion, sclerosis, ankylosis) for each SIJ. Presence/absence of lesions at each time point and decrease/increase in lesions was identified for each patient based on agreement of 2 out of 3 readers. Statistical analyses included kappa coefficient of agreement and McNemar’s test for asymmetry.

Results: 224 patients had MRI and radiographs available. At baseline, concordance for presence or absence of erosion was observed in 162/224 (72.3%) (κ=0.42) (Table). In cases of discordance, erosion was more frequent on MRI (21.4%) than radiographs (6.3%; P<0.0001). Week 104 data were similar to baseline. Decrease in erosion from baseline to 104 weeks was more frequent than increase only when assessed by MRI, and was significantly more frequent on MRI than radiographs. Similarly, decrease in erosion on MRI was significantly more frequent than decrease in sacroiliitis grade.

Conclusion: In patients with early axSpA, erosion was present more often on MRI than on radiographs at baseline and Week 104. Decrease in erosion at Week 104 was noted more frequently on MRI than radiographs.

Table. Concordance between MRI and radiographs; baseline, Week 104, and change between baseline and Week 104

N

Present / Present

Absent / Absent

Absent / Present

Present / Absent

Kappa (95% CI)

P-value for discordance asymmetry*

Erosion on MRI / Erosion on x-ray at BL

224

50 (22.3%)

112 (50.0%)

14 (6.3%)

48 (21.4%)

0.42 (0.30, 0.53)

<0.0001

Erosion on MRI / Erosion on x-ray at Week 104

222

44 (19.8%)

119 (53.6%)

15 (6.8%)

44 (19.8%)

0.41 (0.29, 0.53)

0.0002

Erosion on MRI / sacroiliitis on x-ray at BL

224

60 (26.8%)

97 (43.3%)

29 (12.9%)

38 (17.0%)

0.39 (0.26, 0.51)

0.27

Erosion on MRI / sacroiliitis on x-ray at Week 104

222

56 (25.2%)

99 (44.6%)

35 (15.8%)

32 (14.4%)

0.37 (0.25, 0.50)

0.71

Erosion decrease on MRI / Erosion decrease on x-ray

221

4 (1.8%)

162 (73.3%)

6 (2.7%)

49 (22.2%)

0.06 (-0.05, 0.16)

<0.0001

Erosion increase on MRI / Erosion increase on x-ray

221

2 (0.9%)

187 (84.6%)

17 (7.7%)

15 (6.8%)

0.03 (-0.12, 0.18)

0.72

Erosion decrease on MRI / sacroiliitis grade decrease on x-ray

221

8 (3.6%)

154 (69.7%)

14 (6.3%)

45 (20.4%)

0.08 (-0.05, 0.21)

<0.0001

Erosion increase on MRI / sacroiliitis grade increase on x-ray

221

4 (1.8%)

180 (81.4%)

24 (10.9%)

13 (5.9%)

0.09 (-0.07, 0.25)

0.07

*McNemar’s test.

BL, baseline.


Disclosure: W. P. Maksymowych, Abbvie, Pfizer, 2,Abbvie, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, 5; P. Claudepierre, None; M. de Hooge, MdH Research, 3; R. G. Lambert, BioClinica, 5,AbbVie, 8; R. B. M. Landewé, Abbott/AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol Myers Squibb, Celgene, Janssen (formerly Centocor), Galapagos, GlaxoSmithKline, Novartis, Novo-Nordisk, Merck, Pfizer, Roche, Schering-Plough, TiGenix, UCB, and Wyeth, 5,Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB, and Wyeth, 2,Abbott/AbbVie, Amgen, Bristol Myers Squibb, Janssen (formerly Centocor), Merck, Pfizer, Roche, Schering-Plough, UCB, and Wyeth, 8; A. Molto, None; D. van der Heijde, AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCBAbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringe, 5,Director: Imaging Rheumatology bv, 9; J. F. Bukowski, Pfizer Inc, 1,Pfizer Inc, 3; H. Jones, Pfizer Inc, 1,Pfizer Inc, 3; I. Logeart, Pfizer Inc, 1,Pfizer Inc, 3; L. Marshall, Pfizer Inc, 1,Pfizer Inc, 3; R. Pedersen, Pfizer Inc, 1,Pfizer Inc, 3; A. Szumski, inVentiv Health, 3; B. Vlahos, Pfizer Inc, 1,Pfizer Inc, 3; M. Dougados, Pfizer, AbbVie, UCB, Merck and Lily, 2,Pfizer, AbbVie, UCB, Merck and Lily, 5.

To cite this abstract in AMA style:

Maksymowych WP, Claudepierre P, de Hooge M, Lambert RG, Landewé RBM, Molto A, van der Heijde D, Bukowski JF, Jones H, Logeart I, Marshall L, Pedersen R, Szumski A, Vlahos B, Dougados M. Detection of Structural Lesions on T1 Weighted MRI Versus Radiography of the Sacroiliac Joints in Early Axial Spa: 2-Year Data [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/detection-of-structural-lesions-on-t1-weighted-mri-versus-radiography-of-the-sacroiliac-joints-in-early-axial-spa-2-year-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/detection-of-structural-lesions-on-t1-weighted-mri-versus-radiography-of-the-sacroiliac-joints-in-early-axial-spa-2-year-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology